​

Anebulo Pharmaceuticals Stock (NASDAQ:ANEB)

ForecastOwnershipFinancialsChart

Previous Close

$2.32

52W Range

$0.80 - $3.42

50D Avg

$2.43

200D Avg

$1.70

Market Cap

$101.07M

Avg Vol (3M)

$426.24K

Beta

-0.89

Div Yield

-

ANEB Company Profile

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

2

IPO Date

May 07, 2021

Website

ANEB Performance

ANEB Financial Summary

Jun 25Jun 24Jun 23
Revenue---
Operating Income$-9.22M$-8.31M$-11.78M
Net Income$-8.48M$-8.20M$-11.73M
EBITDA$-9.22M$-8.05M$-11.78M
Basic EPS$-0.25$-0.32$-0.47
Diluted EPS$-0.25$-0.32$-0.47

Fiscal year ends in Jun 25 | Currency in USD

Peer Comparison

TickerCompany
EXOZeXoZymes, Inc.
QNCXQuince Therapeutics, Inc.
SPRBSpruce Biosciences, Inc.
SRZNSurrozen, Inc.
GUTSFractyl Health, Inc. Common Stock
ORMPOramed Pharmaceuticals Inc.
BMEABiomea Fusion, Inc.
MGNXMacroGenics, Inc.
CNTBConnect Biopharma Holdings Limited
ATYRaTyr Pharma, Inc.